Wednesday, March 05, 2025 | 10:37 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Natco Pharma launches hepatitis C drug Velpanat in India

Velpanat is generic version of Epclusa, which contains sofosbuvir (400 mg) & velpatasvir (100 mg)

Natco Pharma launches hepatitis C drug Velpanat in India
Premium

BS B2B Bureau Hyderabad
Natco Pharma Limited has launched a hepatitis C drug – a fixed dose combination of sofosbuvir (400 mg) & velpatasvir (100 mg) – under the brand name of Velpanat in India. Velpanat is the generic version of Epclusa, manufactured by Gilead Sciences Inc globally.

Epclusa is the first all-oral, pan-genotypic, single tablet regimen for the treatment of adults with genotype 1-6 chronic hepatitis C virus (HCV) infection. Epclusa is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype 1, 2, 3, 4, 5, or 6 infection with or without cirrhosis (compensated).

Natco has

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in